Japan· JP-1169008F2065
ペルゴリドメシル酸塩
A pergolide product containing ペルゴリドメシル酸塩, registered in Japan by 沢井製薬, on the national reimbursement list. The same ATC class is registered in 3 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Pergolide is registered in 3 of 19 countries.
Countries holding a registration under ATC N04BC02 (pergolide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Pergolide · ATC N04BC02
3 / 19 countries
- Finlandprice
- Japan
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ペルゴリドメシル酸塩
- Manufacturer
- 沢井製薬
- Country
- Japan (JP)
- ATC code
- N04BC02
- ATC class
- Pergolide
- Defined daily dose
- 3 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for pergolide.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pergolide · interactions on record
81 records
- 1 severe
- 55 moderate
- 25 info
Most severe, free to view
- LorcaserinA08AA11severe
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pergolide in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d3eee4ac-e5be-42ba-8923-be73e26b9c2d GET /v1/drugs/d3eee4ac-e5be-42ba-8923-be73e26b9c2d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５０μｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1169008F2065",
"category": "内用薬",
"price_yen": 57.8,
"generic_name": "ペルゴリドメシル酸塩",
"product_name_jp": null,
"therapeutic_class": "1169",
"transitional_expiry": null
}See everything about pergolide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.